Inhaled Antibiotics in Reanimatology: Problem State and Development Prospects (Review)
https://doi.org/10.15360/1813-9779-2017-5-69-84
Abstract
Nosocomial pneumonia is the second most common nosocomial infection in critical care units and most common in ALV patients (9—27%). The purpose of this literature review is to discuss the latest domestic and foreign body of evidence concerning the use of inhaled antibiotics в critical care. Search for domestic publications (literature reviews, observation studies, double blind randomized studies) was carried out in elibrary.ru database, for foreign — in PubMed. Database for the period of yrs. 2005—2017. The following search enquiries were used: «inhaled antibiotics», «nosocomial pneumonia», «inhaled tobramycin», «inhaled colistin». The analysis includes 67 publications of yrs. 2007—2017 and 1 publication of yr. 2000. The literature review includes drug descriptions, contemporary capabilities of inhaled antibiotic therapy for nosocomial pneumonia, the advantages and drawbacks of this method of treatment. Special attention is focused on the use of inhaled aminoglycosides and inhaled colistin during nosocomial pneumonia in critical care units.
About the Authors
A. N. Kuzovlev
V. A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology
Russian Federation
25 Petrovka Str., Build. 2, Moscow 107031
Russian Federation
25 Petrovka Str., Build. 2, Moscow 107031
A. V. Grechko
V. A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology
Russian Federation
25 Petrovka Str., Build. 2, Moscow 107031
Russian Federation
25 Petrovka Str., Build. 2, Moscow 107031
References
1. Gelfand B.R. (ed.). Nosocomial pneumonia in adults. Russian national guidelines. Moscow: Meditsinskoe Informatsionnoe Agentstvo; 2016: 176. [In Russ.]
2. Bekaert M., Timsit J.F., Vansteelandt S., Depuydt P., Vésin A., Garrouste-Orgeas M., Decruyenaere J., Clec’h C., Azoulay E., Benoit D.; Outcomerea Study Group. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am. J. Respir. Crit. Care Med. 2011; 184: 1133–1139. DOI: 10.1164/rccm.201105-0867OC. PMID: 21852541
3. Golubev A.M., Kuzovlev A.N., Sundukov D.V., Golubev M.A. Morphological characteristics of the lung during lipopolysaccharide and perfluorane inhalation. Obshchaya Reanimatologiya = General Reanimatology. 2015; 11 (1): 6-13. DOI: 10.15360/1813-9779-2015-1-6-13. [In Russ., In Engl.]
4. Moroz V.V., Kuzovlev A.N., Golubev A.M., Stets V.V., Polovnikov S.G. Safety-mode respiratory support in nosocomial pneumonia. Obshchaya Reanimatologiya = General Reanimatology. 2015; 11 (2): 6-17. DOI: 10.15360/1813-9779-2015-2. [In Russ., In Engl.]
5. Chuchalin A.G. (ed.). Respiratory medicine. Manual. Moscow: GEOTAR-Media; 2007: 757. [In Russ.]
6. Valencia M., Torres A. Ventilator-associated pneumonia. Curr. Opin. Crit. Care. 2009; 15 (1): 30-35. DOI: 10.1097/MCC.0b013e3283220e78. PMID: 19186407
7. Chastre J., Wunderink R., Prokocimer P., Lee M., Kaniga K., Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit. Care Med. 2008; 36 (4): 1089–1096. DOI: 10.1097/CCM.0b013e3181691b99. PMID: 18379232
8. Jenkins S., Fisher A., Peterson J., Nicholson S., Kaniga K. Meta-analysis of doripenem vs comparators in patients with Pseudomonasinfections enrolled in four phase III efficacy and safety clinical trials. Curr. Med. Res. Opin. 2009; 25 (12): 3029–3036. DOI: 10.1185/03007990903396790. PMID: 19849650
9. Kollef M., Chastre J., Clavel M., Restrepo M., Michiels B., Kaniga K., Cirillo I., Kimko H., Redman R. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit. Care. 2012; 16 (6): R218. DOI: 10.1186/cc11862. PMID: 23148736
10. Awad S.S., Rodriguez A.H., Chuang Y.C., Marjanek Z., Pareigis A.J., Reis G., Scheeren T.W.L., Sanchez A.S., Zhou X., Saulay M., Engelhardt M. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin. Infect. Dis. 2014; 59 (1): 51–61. DOI: 10.1093/cid/ciu219. PMID: 24723282
11. Flume P., VanDevanter D. Clinical applications of pulmonary delivery of antibiotics. Adv. Drug Deliv. Rev. 2015; 85: 1–6. DOI: 10.1016/j.addr. 2014.10.009. PMID: 25453268
12. Boucher H., Talbot G., Bradley J., Edwards J., Gilbert D., Rice L., Scheld M., Spellberg B., Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009; 48 (1): 1–12. DOI: 10.1086/595011. PMID: 19035777
13. Spellberg B., Bartlett J., Wunderink R., Gilbert D.N. Novel approaches are needed to develop tomorrow’s antibacterial therapies. Am. J. Respir. Crit. Care Med. 2015; 191 (2): 135–140. DOI: 10.1164/rccm.201410-1894OE. PMID: 25590154
14. Imberti R., Cusato M., Villani P., Carnevale L., Iotti G., Langer M., Regazzi M. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest. 2010; 138 (6): 1333–1339. DOI: 10.1378/ chest.10-0463. PMID: 20558557
15. Smith B., Yogaratnam D., Levasseur-Franklin K., Forni A., Fong J. Introduction to drug pharmacokinetics in the critically ill patient. Chest. 2012; 141 (5): 1327–1336. DOI: 10.1378/chest.11-1396. PMID: 22553267
16. Spellberg В. The future of antibiotics. Crit. Care. 2014; 18 (3): 228. DOI: 10.1186/cc13948. PMID: 25043962
17. Amelina E.L., Chuchalin A.G. Inhaling tobramycin in the treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Pulmonologiya. 2009; 5: 120-126. [In Russ.]
18. Belousov Yu.B., Zyryanov S.K., Sokolov A.V. Efficacy and safety of tobramycin solution for inhalations in the treatment of Pseudomonas aeruginosa infection in cystic fibrosis. Pulmonologiya. 2010; 2: 114-119. [In Russ.]
19. Kapranov N.I., Kashirskaya N.Yu., Rodionovich A.M., Amelina E.L., Chuchalin A.G., Gembitskaya T.E., Chermensky A.G., Orlov A.V., Varoli G., Monici Preti P. Clinical importance of special aerosol formulation of tobramycin for treatment of chronic pulmonary disease in patients with cystic fibrosis. Pulmonologiya. 2008; 3: 20-26. [In Russ.]
20. Smelaya T.V., Kuzovlev A.N., Moroz V.V., Golubev A.M., Belopolskaya O.B., Salnikova L.E. Search for common molecular genetic markers of nosocomial pneumonia and acute respiratory distress syndrome. Obshchaya Reanimatologiya = General Reanimatology. 2015; 11 (3): 24-38. DOI: 10.15360/1813-9779-2015-3. [In Russ., In Engl.]
21. Dhand R. The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir. Care. 2007; 52 (7): 866-884. PMID: 17594731
22. Riethmüller J., Herrmann G., Graepler-Mainka U., Hellwig D., Heuer H., Heyder S., Köster H., Kinder B., Kröger K., Paul K., Poplawska K., Melichar V., Smaczny C., Mellies U. Sequential inhalational tobramycin-colistin-combination in CF-patients with chronic P.aeruginosa colonization — an observational study. Cell Physiol. Biochem. 2016; 39 (3): 1141-1151. DOI: 10.1159/000447821. PMID: 27576543
23. Aksamit T., Bandel T.J., Criollo M., De Soyza A., Elborn J.S., Operschall E., Polverino E., Roth K., Winthrop K.L., Wilson R. The RESPIRE trials: two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis. Contemp. Clin. Trials. 2017; 58: 78-85. DOI: 10.1016/j.cct.2017.05.007. PMID: 28495619
24. Ioannidou E., Siempos I., Falagas M. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J. Antimicrob. Chemother. 2007; 60 (6): 1216-1226. DOI: 10.1093/jac/dkm385. PMID: 17934205
25. Hudson R., Olson Blair B. Inhaled antibiotics for gram-negative respiratory infections. Future Med. Chem. 2011; 3 (13): 1663-1677. DOI: 10.4155/fmc.11.114. PMID: 21942255
26. Le J., Ashley E.D., Neuhauser M.M., Brown J., Gentry C., Klepser M.E., Marr A.M., Schiller D., Schwiesow J.N., Tice S., VandenBussche H.L., Wood G.C.; Society of Infectious Diseases Pharmacists Aerosolized Antimicrobials Task Force. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2010; 30 (6): 562-584. DOI: 10.1592/phco.30.6.562. PMID: 20500046
27. Goldstein I., Wallet F., Nicolas-Robin A., Ferrari F., Marquette C.-H., Rouby J.-J. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am. J. Respir. Crit. Care Med. 2002; 166: 1375–1381. DOI: 10.1164/rccm.200204-363OC. PMID: 12406838
28. Weers J. Inhaled antimicrobial therapy — barriers to effective treatment. Adv. Drug Deliv. Rev. 2015; 85: e3–e5. DOI: 10.1016/j.addr.2015.04.014. PMID: 25913567
29. Lu Q., Yang J., Liu Z., Gutierrez C., Aymard G., Rouby J.; Nebulized Antibiotics Study Group. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med. 2011; 184 (1): 106-115. DOI: 10.1164/rccm.201011-1894OC. PMID: 21474643
30. Drlica K., Zhao X. Mutant selection window hypothesis updated. Clin. Infect. Dis. 2007; 44 (5): 681–688. DOI: 10.1086/511642. PMID: 17278059
31. Niederman M.S., Chastre J., Corkery K., Fink J.B., Luyt C.E., García M.S. Bay41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with gram-negative pneumonia. Intensive Care Med. 2012; 38 (2): 263–271. DOI: 10.1007/s00134-011-2420-0. PMID: 22147112
32. Chastre J., Luyt C.-E. Optimising the duration of antibiotic therapy for ventilator-associated pneumonia. Eur. Respir. Rev. 2007; 16: 40–44. DOI: 10.1183/09059180.00010303
33. Korbila I., Michalopoulos A., Rafailidis P.I., Nikita D., Samonis G., Falagas M.E. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin. Microbiol. Infect. 2010; 16 (8): 1230-1236. DOI: 10.1111/j.1469-0691.2009.03040.x. PMID: 19732088
34. Michalopoulos A., Papadakis E. Inhaled anti-infective agents: emphasis on colistin. Infection. 2010; 38 (2): 81-88. DOI: 10.1007/s15010-009-9148-6. PMID: 20191398
35. Tumbarello M., De Pascale G., Trecarichi E., De Martino S., Bello G., Maviglia R. Spanu T., Antonelli M. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gramnegative bacteria. Chest. 2013; 144 (6): 1768-1775. DOI: 10.1378/chest.13-1018. PMID: 23989805
36. Doshi N.M., Cook C.H., Mount K.L., Stawicki S.P., Frazee E.N., Personett H.A., Schramm G.E., Arnold H.M., Murphy C.V. Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study. BMC Anesthesiol. 2013; 13 (1): 45. DOI: 10.1186/1471-2253-13-45. PMID: 24274315
37. Hallal A., Cohn S.M., Namias N., Habib F., Baracco G., Manning R.J., Crookes B., Schulman C.I. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg. Infect. (Larchmt.). 2007; 8 (1): 73–82. DOI: 10.1089/sur.2006.051. PMID: 17381399
38. Mohr A.M., Sifri Z.C., Horng H.S., Sadek R., Savetamal A., Hauser C.J., Livingston D.H. Use of aerosolized aminoglycosides in the treatment of gram-negative ventilator-associated pneumonia. Surg. Infect. (Larchmt.). 2007; 8 (3): 349–357. DOI: 10.1089/sur.2006.041. PMID: 17635058
39. Czosnowski Q.A., Wood G.C., Magnotti L.J., Croce M.A., Swanson J.M., Boucher B.A., Fabian T.C. Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy. 2009; 29 (9): 1054-1060. DOI: 10.1592/phco.29.9.1054. PMID: 19698010
40. Rello J., Solé-Lleonart C., Rouby J., Chastre J., Blot S., Poulakou G., Luyt C., Riera J., Palmer L., Pereira J., Felton T., Dhanani J., Bassetti M., Welte T., Roberts J. Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin. Microbiol. Infect. 2017; pii: S1198-743X(17)30219-7. DOI: 10.1016/j.cmi.2017.04.011. PMID: 28412382
41. Kalil A., Metersky M., Klompas M., Muscedere J., Sweeney D., Palmer L., Napolitano L., O’Grady N., Bartlett J., Carratalà J., El Solh A., Ewig S., Fey P., File T., Restrepo M., Roberts J., Waterer G., Cruse P., Knight S., Brozek J. Executive Summary: Management of Adults With Hospitalacquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin. Infect. Dis. 2016; 63 (5): 575-582. DOI: 10.1093/cid/ciw504. PMID: 27521441
42. Palmer L.B. Aerosolized antibiotics in the intensive care unit. Clin. Chest. Med. 2011; 32 (3): 559-574. DOI: 10.1016/j.ccm.2011.05.012. PMID: 21867823
43. Arnold H., Sawyer A., Kollef M. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir. Care. 2012; 57 (8): 1226-1233. DOI: 10.4187/respcare.01556. PMID: 22349038
44. Rigatto M., Ribeiro V., Konzen D., Zavascki A. Comparison of polymyxin B with other antimicrobials in the treatment of ventilator-associated pneumonia andtracheobronchitis caused by Pseudomonas aeruginosa or Acinetobacter baumannii. Infection. 2013; 41 (2): 321-328. DOI: 10.1007/s15010-012-0349-z. PMID: 23124906
45. Le Conte P., Potel G., Clementi E., Legras A., Villers D., Bironneau E., Cousson J., Baron D. Administration of tobramycin aerosols in patients with nosocomial pneumonia: a preliminary study. Presse. Med. 2000; 29 (2): 76–78. PMID: 10682031
46. Kuzovlev A.N., Moroz V.V., Golubev A.M. Inhaled antibiotics in treatment of nosocomial pneumonia. Anesteziologiya i Reanimatologiya. 2015; 60 (4): 55-62. PMID: 26596034. [In Russ.]
47. Lu Q., Luo R., Bodin L., Yang J., Zahr N., Aubry A., Golmard J.L., Rouby J.J.; Nebulized Antibiotics Study Group. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology. 2012; 117 (6): 1335–1347. DOI: 10.1097/ALN.0b013e31827515de. PMID: 23132092
48. Ghannam D.E., Rodriguez G.H., Raad I.I., Safdar A. Inhaled aminoglycosides in cancer patients with ventilator-associated gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur. J. Clin. Microbiol. Infect Dis. 2009; 28 (3): 253-259. DOI: 10.1007/s10096-008-0620-5. PMID: 18752007
49. Kuzovlev A.N., Moroz V.V., Golubev A.M., Polovnikov S.G. Inhaled tobramycin in the treatment of ventilator-associated pneumonia. Klinicheskaya Farmakologiya i Terapiya. 2014; 23 (4): 52-58. [In Russ.]
50. Gurjar M. Colistin for lung infection: an update. J. Intensive Care. 2015; 3 (1): 3. DOI: 10.1186/s40560-015-0072-9. PMID: 25705428
51. Liu D., Zhang J., Liu H., Zhu Y., Qu J. Intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: a systematic review and meta-analysis. Int. J. Antimicrob. Agents. 2015; 46 (6): 603-609. DOI: 10.1016/j.ijantimicag.2015.09.011. PMID: 26607337
52. Rattanaumpawan P., Lorsutthitham J., Ungprasert P., Angkasekwinai N., Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J. Antimicrob. Chemother. 2010; 65 (12): 2645–2649. DOI: 10.1093/jac/dkq360. PMID: 20876621
53. Valachis A., Samonis G., Kofteridis D. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit. Care Med. 2015; 43 (3): 527-533. DOI: 10.1097/CCM.0000000000000771. PMID: 25493971
54. Florescu D., Qiu F., McCartan M., Mindru C., Fey P., Kalil A. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin. Infect. Dis. 2012; 54 (5): 670–680. DOI: 10.1093/cid/cir934. PMID: 22322268
55. Kofteridis D., Alexopoulou C., Valachis A., Maraki S., Dimopoulou D., Georgopoulos D., Samonis G. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin. Infect. Dis. 2010; 51 (11): 1238-1244. DOI: 10.1086/657242. PMID: 20973727
56. Demirdal T., Sari U., Nemli S. Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii? Ann. Clin. Microbiol. Antimicrob. 2016; 15: 11. DOI: 10.1186/s12941-016-0123-7. PMID: 26911714
57. Abdellatif S., Trifi A., Daly F., Mahjoub K., Nasri R., Ben Lakhal S. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. Ann. Intensive Care. 2016; 6 (1): 26. DOI: 10.1186/s13613-016-0127-7. PMID: 27033711
58. Shabanov A.K., Khubutiya M.Sh., Bulava G.V., Beloborodova N.V., Kuzovlev A.N., Grebenchikov O.A., Kosolapov D.A., Shpitonkov M.I. Time course of changes in the level of procalcitonin in the development of nosocomial pneumonia in victims with severe concomitant injury in an intensive care unit. Obshchaya Reanimatologiya = General Reanimatology. 2013; 9 (5): 11-18. DOI: 10.15360/1813-9779-2013-5-11. [In Russ., In Engl.]
59. Migiyama Y., Hirosako S., Tokunaga K., Migiyama E., Tashiro T., Sagishima K., Kamohara H., Kinoshita Y., Kohrogi H. Aerosolized tobramycin for Pseudomonas aeruginosa ventilator-associated pneumonia in patients with acute respiratory distress syndrome. Pulm. Pharmacol. Ther. 2017; 45: 142-147. DOI: 10.1016/j.pupt.2017.04.008. PMID: 28450200
60. Smelaya T.V., Belopolskaya O.B., Smirnova S.V., Kuzovlev A.N., Moroz V.V., Golubev A.M., Pabalan N.A., Salnikova L.E. Genetic dissection of host immune response in pneumonia development and progression. Sci. Rep. 2016; 6: 35021. DOI: 10.1038/srep35021. PMID: 27725770
61. Sievert D., Ricks P., Edwards J., Schneider A., Patel J., Srinivasan A., Kallen A., Limbago B., Fridkin S.; National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect. Control Hosp. Epidemiol. 2013; 34 (1): 1-14. DOI: 10.1086/668770. PMID: 23221186
62. Montgomery A., Rhomberg P., Abuan T., Walters K., Flamm R. Amikacin/fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics. Antimicrob. Agents Chemother. 2014; 58 (7): 3708–3713. DOI: 10.1128/AAC.02779-13. PMID: 24752276
63. Montgomery A., Rhomberg P., Abuan T., Walters K., Flamm R. Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible gram-negative respiratory tract pathogens. Antimicrob. Agents Chemother. 2014; 58 (7): 3714–3719. DOI: 10.1128/AAC.02780-13. PMID: 24752275
64. Montgomery A., Vallance S., Abuan T., Tservistas M., Davies A. A randomized double-blind placebo-controlled dose-escalation Phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI Investigational eFlow® Inline Nebulizer System in mechanically ventilated patients. J. Aerosol. Med. Pulm. Drug Deliv. 2014; 27 (6): 441–448. DOI: 10.1089/jamp.2013.1100. PMID: 24383962
65. Tolker-Nielsen T., Høiby N. Extracellular DNA and F-actin as targets in antibiofilm cystic fibrosis therapy. Future Microbiol. 2009; 4 (6): 645-647. DOI: 10.2217/fmb.09.38. PMID: 19659420
66. Kadrichu N., Corkery K., Dang T., Challoner P. Performance of amikacin inhale: impact of supplemental oxygen and device orientation. Crit. Care. 2015; 19 (Suppl 1): P120. DOI: 10.1186/cc14200
67. Esposito S., Rosazza C., Sciarrabba C.S., Principi N. Inhaled antibiotic therapy for the treatment of upper respiratory tract infections. J. Aerosol. Med. Pulm. Drug Deliv. 2017; 30 (1): 14-19. DOI: 10.1089/jamp.2016.1300. PMID: 273362290
68. Bassetti M., Luyt C.E., Nicolau D.P., Pugin J. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann. Intensive Care. 2016; 6 (1): 35. DOI: 10.1186/s13613-016-0140-x. PMID: 27090532
Review
For citations:
Kuzovlev A.N., Grechko A.V. Inhaled Antibiotics in Reanimatology: Problem State and Development Prospects (Review). General Reanimatology. 2017;13(5):69-84. https://doi.org/10.15360/1813-9779-2017-5-69-84
Views:
1227
Email this article 